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Summary
We used two-locus segregation analysis to test whether
an unknown genetic defect interacts with protein C de-
ficiency to increase susceptibility to venous thromboem-
bolic disease in a single large pedigree. Sixty-seven ped-
igree members carry a His107Pro mutation in the
protein C gene, which reduces protein C levels to a mean
of 46% of normal. Twenty-one carriers of the mutation
and five other pedigree members had verified throm-
boembolic disease. We inferred the presence in this ped-
igree of a thrombosis-susceptibility gene interactingwith
protein C deficiency, by rejecting the hypothesis that the
cases of thromboembolic disease resulted from protein
C deficiency alone and by not rejecting Mendelian trans-
mission of the interacting gene. When coinherited with
protein C deficiency, the interacting gene conferred a
probability of a thrombotic episode of ∼79% for men
and ∼99% for women, before age 60 years.
Introduction
Normal coagulation has been described as a “cascade”
or “waterfall” in which a series of precisely regulated
enzymatic reactions convert a set of proenzymes into
their active forms (Mann et al. 1995). Bleeding disorders
result from deficiencies of certain components in the cas-
cade; for example, factor VIII deficiency causes hemo-
philia A (Reiner and Davie 1995). In contrast, deficien-
cies of other components, such as protein C, increase
the risk of venous thromboembolic disease (Florell and
Rodgers 1997).
Protein C is a vitamin K–dependent glycoprotein that,
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when activated, cleaves the procoagulant protein factor
V, thereby inactivating it (Esmon 1993). The protein C
gene has been isolated, characterized, and assigned to
chromosome 2 (Beckmann et al. 1985; Foster et al. 1985;
Plutzky et al. 1986; Kato et al. 1988). At least 160 mu-
tations causing protein C deficiency have been identified
(Reitsma 1996).
Other common causes of inherited venous throm-
boembolic disease include activated–protein C resis-
tance, deficiencies of protein S and antithrombin (Florell
and Rodgers 1997), and elevated plasma prothrombin.
Activated–protein C resistance usually is due to an
Arg506Gln mutation in factor V (factor VLeiden), which
eliminates the activated–protein C cleavage site (Dahl-
ba¨ck et al. 1993; Dahlba¨ck 1994). As with protein C
deficiency, many mutations have been identified as
causes of protein S deficiency (Simmonds et al. 1996)
and antithrombin deficiency (Lane et al. 1997). A
G20210A prothrombin mutation in the 3′ UTR of the
prothrombin gene is one cause of elevated plasma pro-
thrombin (Poort et al. 1996).
Despite the fact that inherited venous thromboembolic
disease has been attributed to single genetic defects, the
interaction of two genetic defects often may be respon-
sible (Miletich et al. 1993). Since its identification, factor
VLeiden has been found to be common among individuals
whose venous thromboembolic disease previously had
been attributed solely to deficiencies of protein C (Koe-
leman et al. 1994; Gandrille et al. 1995; Brenner et al.
1996), protein S (Koeleman et al. 1995; Zo¨ller et al.
1995a), or antithrombin (van Boven et al. 1996). Other
pairs of genetic defects also have been reported for
thrombosis patients (Gandrille et al. 1988; Berruyer et
al. 1994; Zo¨ller et al. 1995b; Beauchamp et al. 1996;
Zu¨ger et al. 1996). In this study, we used two-locus
segregation analysis to test for evidence of a genetic de-
fect that interacts with protein C deficiency to increase
the risk of venous thromboembolic disease in a single
large pedigree with 283 studied members.
Subjects and Methods
The sample used in the analysis consisted of a single
large pedigree, which was ascertained through a 13-year-
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old boy who was suspected to have had a venous throm-
botic episode. Through questioning, his mother reported
her own experience with a venous thrombotic episode,
at age 17 years; her low protein C level prompted us to
study her relatives, making her the true proband of the
pedigree. We studied all available descendants of the
proband’s paternal grandparents, up to six generations
in some lines, and verified a high incidence of venous
thromboembolic disease in pedigree members (Bovill et
al. 1989); the pedigree has been extended to include
descendants of the proband’s paternal grandmother’s
sister. The family resides primarily in the Northeast
Kingdom region of Vermont. Both grandparents were
part Abenaki American Indian and part French Cana-
dian, and marriages among their descendants have oc-
curred primarily within those communities. This study
was approved by the Human Experimentation Com-
mittees of the University of Vermont College of Medicine
and Beth Israel Hospital, Boston.
Each subject in the study completed a questionnaire
and an interview, thereby providing information on
thrombotic risk factors and the occurrence of venous
thrombotic episodes. We classified subjects as having
verified thromboembolic disease if they reported being
hospitalized and treated for deep venous thrombosis;
objective, corroborative tests were available in 190% of
the cases. We classified subjects as having equivocal
thromboembolic disease if they reported either an un-
hospitalized thrombotic episode or superficial throm-
bophlebitis. In the absence of any evidence of venous
thrombotic episodes, subjects were classified as unaf-
fected. Plasma concentrations of protein C were deter-
mined by immunoassay and were normalized to the
mean of a normal plasma pool composed of 54 control
subjects (Bovill et al. 1989).
We used likelihood analysis (Elston and Stewart 1971)
to test for evidence of a genetic defect that interacts with
protein C deficiency to increase susceptibility to venous
thrombosis. Likelihoods were approximated (Hasstedt
1993) by use of the Pedigree Analysis Package (Hasstedt
1994) and the maxima obtained with the Nonlinear Pro-
gramming-Systems Optimization Laboratory (Gill et al.
1986). Correction was made for ascertainment, by di-
vision of the likelihood of the pedigree by the probability
of the proband’s phenotype. Hypothesis testing was per-
formed by comparison of the likelihood of a submodel
to the likelihood of a more general model. Under certain
conditions, 2 multiplied by the natural logarithm of
the ratio of the likelihoods has an asymptotic x2
distribution.
We assumed that an unmeasurable quantitative lia-
bility variable underlies thrombosis susceptibility (Mor-
ton and MacLean 1974). The liability variable was dis-
tributed as a mixture of normal densities, one for each
genotype, with the mixture proportions equal to the ge-
notype frequencies. The population incidence for each
age interval determined a point on the liability scale such
that the weighted sum of the areas between adjacent
points, under the normal curves for all genotypes,
equaled the venous thrombosis incidence for that age
interval, with younger ages corresponding to higher li-
ability. For an affected individual, the probability of a
particular genotype equaled the integral of the appro-
priate normal curve between the two points, on the li-
ability scale, bracketing the individual’s age at first
thrombotic episode. For an unaffected individual, the
probability of a particular genotype equaled the integral
of the appropriate normal curve from  to the point,
on the liability scale, marking the upper end of the age
range bracketing the age when the individual was last
known to be free of thrombosis.
The genetic model included two unlinked major loci,
polygenes, and random environmental factors specific to
the individual. We assumed that each major locus had
two alleles in Hardy-Weinberg equilibrium. The first ma-
jor locus represented the protein C gene, with the geno-
types defined by mutation analysis; the allele frequency
at this locus was fixed at .0025, to correspond to a
prevalence of protein C deficiency of 1/200 (Miletich et
al. 1987). The second major locus represented an un-
known interacting gene.
The parameters of the model included the frequency,
q, of the interacting genetic defect; the dominance, dm
and df, of the interacting genetic defect, in males and
females, respectively; displacement tCm and tCf, for pro-
tein C in males and females, respectively; displacement
tIm and tIf, for the interacting genetic defect in males and
females, respectively; polygenic heritability, h2; and par-
ent-to-offspring transmission probabilities t1, t2, and t3,
for the three genotypes of the interacting gene (Boyle
and Elston 1979; Lalouel et al. 1983). Displacement
equaled the difference in within-genotype SDs between
the mean liabilities of the two types of homozygotes at
one locus. We assumed additivity of displacement across
loci; that is, the displacement for both loci together
equaled the sum of the displacement for the protein C
gene and the displacement for the interacting gene. Dom-
inance equaled the difference between the mean liability
of heterozygotes and the mean liability of unaffected
homozygotes, relative to the displacement at the locus;
dominance at the protein C locus was fixed at 1. Poly-
genic heritability equaled the proportion of the variance
within major-locus genotypes that was due to polygenic
inheritance. Mendelian inheritance specified ,t  11
, and .1t  t  02 32
To test the hypothesis that protein C deficiency alone
determines thrombosis susceptibility, we compared the
likelihood maximized by restricting , ,q  0 d  0m
, , , , , and with1d  0 t  0 t  0 t  1 t  t  0f Im If 1 2 32
the likelihood maximized by restricting , ,1t  1 t 1 2 2
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Table 1
Number of Pedigree Members with Verified or Equivocal
Thrombosis and Population Incidence (per 100,000) of Verified
Thrombosis, by Sex and by Age at First Thrombotic Episode
AGE AT
FIRST
EPISODE
(YEARS)
NO. OF PEDI-
GREE MEMBERS
WITH VERIFIED
THROMBOSIS
NO. OF PEDI-
GREE MEM-
BERS WITH
EQUIVOCAL
THROMBOSIS
POPULATION IN-
CIDENCE (PER
100,000) OF
VERIFIED
THROMBOSISa
M F M F M F
10–19 0 4 2 0 2 0b
20–29 2 6 0 4 17 13
30–39 2 3 4 4 30 19
40–49 4 0 2 2 31 8
50–59 3 0 1 0 49 33
60–69 1 0 0 2 174 115
70–79 0 1 0 0 276 210
80 0 0 0 0 334 327
NOTE.—M  male; F  female.
a Data from the study by Anderson et al. (1991); also see figure 2.
b Set at 1/100,000 in the analysis, because there were patients in
the pedigree in that sex and age category.
Figure 1 Distribution of protein C levels among carriers of the
His107Pro protein C mutation, by thrombosis diagnosis.
and . To test Mendelian transmission and envi-t  03
ronmental nontransmission of the interacting genetic de-
fect, we compared the likelihoods maximized by re-
stricting , , , and1t  1 t  t  0 1 q  t  t 1 2 3 1 22
, respectively, with the likelihood maximized withoutt3
constraints. We inferred an interacting genetic defect by
rejecting the hypotheses of thrombosis susceptibility be-
ing determined by protein C deficiency alone or by pro-
tein C deficiency in conjunction with a nontransmitted
environmental factor, while not rejecting the hypothesis
of Mendelian transmission of an interacting genetic de-
fect. The tests of recessivity and dominance compared
the likelihoods maximized by restricting d  d  0m f
and with the likelihood maximized whend  d  1m f
dm and df were unrestricted, while t1, t2, and t3 were
restricted to 1, , and 0, respectively.12
Results
Table 1 presents the sex and age distributions of 26
pedigree members with verified and 21 pedigree mem-
bers with equivocal thrombotic episodes. In the segre-
gation analysis, individuals with verified thrombotic ep-
isodes were classified as “affected,” and individuals with
equivocal thrombotic episodes were classified as “un-
known.” Age at first thrombotic episode was within the
range 17–76 years, with a mean age of 35 years.
Table 1 also includes the sex- and age-specific inci-
dences of venous thrombosis in the general population.
The segregation analysis constrained the genetic model
to correspond to these incidence figures. Although
thrombotic episodes in the general population usually
occur at age x60 years, all thrombotic episodes in the
pedigree occurred earlier, with two exceptions, at ages
61 years and 76 years.
Sixty-seven pedigree members, including the proband
but not her son, carry a His107Pro mutation in the pro-
tein C gene (Tomczak et al. 1994); 64 carriers were iden-
tified through mutation screening, and the other 3 car-
riers were their ancestors. This analysis ignored a
Thr298Met mutation in the protein C gene (Tomczak
et al. 1994), which was found in the wife of a His107Pro
mutation carrier and in two of their daughters. Figure
1 shows the distribution, by disease status, of protein C
levels in the 61 measured His107Pro mutation carriers.
Protein C levels were within the ranges 4%–69% of
normal in 20 verified thrombosis patients, 25%–69%
of normal in 4 equivocal thrombosis patients, and
16%–109% of normal in 37 unaffected mutation car-
riers. Warfarin therapy accounts for some of the very
low protein C measurements. Protein C levels met or
exceeded the lower limit of the normal range (66% of
normal) in 7 of the His107Pro mutation carriers.
Twenty-one mutation carriers and five other pedigree
members suffered verified thrombotic episodes. Figure 2
presents the distribution of 24 verified thrombosis pa-
tients, by age at first thrombotic episode, percentage of
normal protein C level, and mutation status; the other
two verified thrombosis patients lacked protein C meas-
urements. Thrombotic episodes in the pedigree members
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Figure 2 Distribution of protein C levels among male and female
carriers and noncarriers of the His107Pro protein C mutation, by age
at first thrombotic episode.
Table 2
Number of Pedigree Members, by Affection and Carrier Status, and
Age Range of Unaffecteds
GROUP
NO. OF PEDIGREE MEMBERS
AGE OF UNAFFECTEDS
(YEARS)
Studied Affected Carrier Minimum Maximum
Generation:
II 6 4 2 41 65
III 30 11 18 36 81
IV 116 10 34 11 57
V 108 1 13 1 38
VI 7 0 0 3 15
Spouses 16 0 0 35 84
Total 283 26 67 ) )
tended to occur earlier in women than in men and were
precipitated by pregnancy or oral contraceptive use
(Trauscht–Van Horn et al. 1992).
An additional 257 pedigree members and spouses with
no history of thrombosis were classified as unaffected,
resulting in a total sample size of 283 for the segregation
analysis (table 2). An earlier version of the complete
pedigree has been published elsewhere (Bovill et al.
1989); figure 3 shows a selected branch, to illustrate the
observed inheritance patterns. Individuals 1 and 2 both
transmitted the His107Pro mutation; yet, thrombotic ep-
isodes occurred only among the offspring of individual
1, who also was affected. Individual 5 experienced a
thrombotic episode in the absence of the His107Pro mu-
tation, but four offspring have been free of thrombosis,
although they are still young enough to remain at risk.
As does figure 1, figure 3 shows that not all His107Pro
mutation carriers experience a thrombotic episode. As
does figure 2, figure 3 shows thrombotic episodes oc-
curring primarily, but not exclusively, in mutation car-
riers. In addition, figure 3 illustrates that thrombotic
episodes never occur in an individual whose parents had
no history of thrombotic episodes, which also is true of
the complete pedigree.
We inferred that a thrombosis-susceptibility gene in-
teracts with protein C deficiency, by rejecting the hy-
potheses that thrombosis susceptibility results from pro-
tein C deficiency alone ( , ) or2x  27.72 P  .000041(5)
that a nontransmitted environmental factor interacts
with protein C deficiency ( , ),2x  19.57 P  .00021(3)
while not rejecting Mendelian transmission of an inter-
acting genetic defect ( , ). The last x22x  1.47 P  .69(3)
statistic indicates that the transmission probabilities, es-
timated as , , andt  .990 .019 t  .371 .1221 2
, do not differ significantly from Mendelian values.t  03
We inferred dominant inheritance by rejecting the hy-
pothesis of recessive inheritance ( ,2x  24.58 P (2)
) but not of dominant inheritance ( 2.0000046 x (2)
, ). Table 3 summarizes all the models tested.0.00 P 1 .05
The parameter estimates for the inferred dominant
model were ,q  .00033 0.00027 t  2.80Cm
, , ,0.53 t  2.15 0.53 t  1.13 0.57 t Cf Im If
, and . Table 4 gives the23.55 0.57 h  .083 .271
penetrances that correspond to the parameter estimates.
In the men, protein C deficiency exerted the larger effect,
with an estimated penetrance, by age 60 years, of 37%,
compared with 2% for the interacting genetic defect. In
the women, the interacting genetic defect had the larger
effect, with an estimated penetrance, by age 60 years,
of 61%, compared with 13% for protein C deficiency.
Protein C deficiency interacting with the unknown ge-
netic defect resulted in a penetrance, by age 60 years, of
79% in men and 99% in women.
Discussion
Homozygosity for protein C deficiency causes massive
venous thrombosis and purpura fulminans in newborns
(Marlar et al. 1989). Nevertheless, heterozygosity for
protein C deficiency does not appear to increase the risk
of venous thrombosis in individuals identified either
through a homozygous relative (Branson et al. 1983;
Estelle´s et al. 1984; Seligsohn et al. 1984; Marciniak et
al. 1985) or through population screening (Miletich et
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Figure 3 Selected descendants of the parents of the proband (individual 3). Unaffected individuals whose current age is not given were
not studied.
al. 1987; Tait et al. 1995; McColl et al. 1996). On the
other hand, heterozygosity is frequent in venous throm-
bosis patients (Gladson et al. 1988; Koster et al. 1995),
and venous thrombosis is frequent in the heterozygous
relatives of heterozygous venous thrombosis patients
(Griffin et al. 1981; Broekmans et al. 1983; Horellou et
al. 1984; Pabinger and Schneider 1996). These apparent
inconsistencies are resolved if venous thrombotic epi-
sodes occur rarely in individuals with a single genetic
defect but frequently in individuals with two genetic de-
fects (Miletich et al. 1993; Florell and Rodgers 1997;
Seligsohn and Zivelin 1997). Nevertheless, our inferred
model suggests a slightly increased risk from a single
genetic defect, but the estimates were based on small
numbers.
The inferred model assumed that the effect due to the
coinheritance of an interacting genetic defect in con-
junction with the His107Pro mutation in the protein C
gene equaled the sum of the effects due to each of the
genes alone. The additivity occurred on an unmeasurable
quantitative liability scale assumed to underlie throm-
bosis susceptibility (Morton and MacLean 1974). Ad-
ditivity on the liability scale produces an interactive ef-
fect on the penetrances, but to a degree that is less than
multiplicative (Risch et al. 1993). The effect of the ad-
ditivity assumption was to produce a penetrance for the
two defects combined that was substantially higher in
younger patients but only slightly higher in older patients
than that for either defect alone. Nevertheless, caution
is advised in interpretation of the penetrance estimates,
since the validity of the additivity assumption is un-
known, the incidence figures (which constrained the pen-
etrance estimates) derive from a population different
than the pedigree, and only a small number of throm-
bosis patients contributed to the penetrance estimates.
The eventual identification of carriers of the interacting
genetic defect will allow refinement of the penetrance
estimates.
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Table 3
Parameter Estimates and x2 Statistics for Each Model
PARAMETER
PARAMETER VALUE, BY MODEL FOR INTERACTING GENETIC DEFECTa
None Recessive Dominant Codominant Environmental General
q [0] .0804 .0003 .0003 .1120 .0003
t1 [1] [1] [1] [1] [ ]1 q .990
t2 [.5] [.5] [.5] [.5] [ ]1 q .371
t3 [0] [0] [0] [0] [ ]1 q (0)
dm [0] [0] [1] (1) .819 (1)
df [0] [0] [1] (1) (1) (1)
tCm .707 1.068 2.799 2.799 4.186 2.803
tCf 1.671 1.656 2.151 2.151 1.676 2.016
tIm [0] 2.394 1.135 1.135 4.726 1.132
tIf [0] .097 3.549 3.549 (1) 2.921
h2 (1) (1) .083 .083 (1) .022
x2 27.72∗ 24.58∗ .00 1.47 19.57∗ )
df 5 2 2 3 3 )
Comparison
model Codominant Codominant Codominant General General )
a Square brackets indicate fixed parameter values. Parentheses indicate boundary parameter estimates.
∗ .P ! .0005
Table 4
Penetrance of Verified Thrombosis, by Genotype, Sex, and Age at
First Thrombotic Episode
AGE AT
FIRST
EPISODE
(YEARS)
PENETRANCE (%), BY PRESENCE () OR ABSENCE () OF
PROTEIN C DEFICIENCY/INTERACTING GENETIC DEFECT
/ / / /
M F M F M F M F
10–19 .00 .00 .40 .01 .00 1.23 6.42 46.16
20–29 .00 .00 4.13 .76 .03 15.17 27.38 86.91
30–39 .00 .00 13.08 3.79 .27 35.27 50.48 96.19
40–49 .03 .02 24.86 7.49 .96 48.59 67.57 98.28
50–59 .09 .05 37.46 13.20 2.36 61.07 79.25 99.25
60–69 .32 .19 52.76 22.72 5.53 74.21 88.57 99.75
70–79 .83 .52 65.69 34.14 10.38 83.88 93.81 99.92
80 1.70 1.19 75.13 45.67 16.21 90.13 96.51 99.97
NOTE.—M  male; F  female.
There are many candidates for the inferred interacting
gene. Factor VLeiden (Koeleman et al. 1994; Gandrille et
al. 1995; Brenner et al. 1996) and dysfibrinogenemia
(Gandrille et al. 1988) reportedly increase venous throm-
botic risk, through interaction with protein C deficiency.
However, we ruled out factor VLeiden, through mutation
screening, and failed to find dysfunctional fibrinogen
during functional analysis. In addition, we ruled out pro-
tein S, antithrombin, plasminogen activator inhibitor-1,
and plasminogen activator inhibitor-3 as candidates for
interaction with protein C deficiency in this pedigree, by
finding normal levels in affected pedigree members. Nev-
ertheless, numerous other genes for protein products that
contribute to the coagulation cascade remain as candi-
dates (Miletich et al. 1993).
If none of the candidate genes prove to be the gene
interacting with protein C deficiency in this pedigree, we
can localize the gene by using linkage analysis. However,
a sample size with sufficient power is more difficult to
obtain for analysis of a two-gene disease than for anal-
ysis of a single-gene disease. For only 13 of the 67 ped-
igree members who carry the His107Pro mutation, the
probability of also carrying the interacting genetic defect
is 150%. We have begun to extend the pedigree to de-
scendants of the siblings of the proband’s paternal
grandmother. However, if each grandparent contributed
one genetic defect, only their common descendants can
inherit both defects. We have attributed the His107Pro
mutation in the protein C gene to the proband’s grand-
mother by detecting the mutation in eight descendants
of her sister. However, the source of the interacting ge-
netic defect remains indeterminate at this point, despite
the testing of 34 members of this branch of the pedigree.
Three verified venous thrombotic episodes among the
sister’s descendants suggest but do not confirm that the
interacting gene also derived from the grandmother.
In summary, we inferred a gene that interacts with
protein C deficiency to increase the risk of venous throm-
bosis in a large pedigree. The interacting gene remains
to be identified, but this study justifies initiation of a
search for the gene by the testing of candidate loci and
the performance of a genomewide screen.
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